Clinical trials
Immune Checkpoint Inhibitor clinical trials
Below are recruiting immune checkpoint inhibitor clinical trials, each written for real people, not researchers. We’re tracking 173 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06771544RecruitingPhase 2
Cyclophosphamide and pembrolizumab for advanced melanoma
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Orange, CaliforniaAges 18 years+ - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT06206707Recruiting
FMT for Diarrhea and Colitis After Immunotherapy
This trial tests whether a treatment called fecal microbiota transplant (FMT) — transferring healthy gut bacteria — can help relieve diarrhea and colitis caused by immunotherapy drugs. If you have melanoma or kidney cancer and are experiencing diarrhea after immunotherapy, this study may offer a new option.
Aarhus NAges 18 years+ - NCT03847649RecruitingPhase 2
Durvalumab for cancer after stopping immune therapy due to side effects
This Phase 2 trial tests whether durvalumab (an immunotherapy) can still help treat advanced cancer after you had to stop an earlier immune checkpoint medicine because of immune-related side effects. If you’re already on a durvalumab-based study, Substudy B also looks at continuing durvalumab (with or without tremelimumab) when it’s safe for you.
Edmonton, AlbertaAges 18 years+ - NCT05392413Recruiting
Predicting who benefits from PD-1 antibody for esophageal cancer
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
GuangzhouAges 18–75
Hear when a new Immune Checkpoint Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint inhibitor?
- Yes. Clin2 currently lists 173 recruiting immune checkpoint inhibitor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint inhibitor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint inhibitor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.